Coherus Oncology (CHRS) Total Liabilities (2012 - 2026)

Coherus Oncology has disclosed Total Liabilities across 15 years of filings, most recently posting $187.4 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $187.4 million, down 66.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $187.4 million (down 66.21% YoY), and the FY2025 annual result was $197.3 million, down 66.01% from the prior year.
• Total Liabilities came in at $187.4 million for Q1 2026 at Coherus Oncology, down from $197.3 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $845.4 million in Q1 2024 to a low of $187.4 million in Q1 2026.
• The 5-year median for Total Liabilities is $593.0 million (2024), against an average of $568.5 million.
• Across the five-year window, Total Liabilities jumped 41.15% in 2024 and slumped 66.21% in 2026, its largest moves.
• Coherus Oncology's Total Liabilities stood at $618.3 million in 2022, then surged by 33.12% to $823.0 million in 2023, then fell by 29.47% to $580.5 million in 2024, then tumbled by 66.01% to $197.3 million in 2025, then declined by 5.03% to $187.4 million in 2026.
• The last three Total Liabilities figures came in at $187.4 million (Q1 2026), $197.3 million (Q4 2025), and $428.7 million (Q3 2025), per Business Quant data.